Risperidone

Generic Name
Risperidone
Brand Names
Perseris, Risperdal, Rykindo, Uzedy, Okedi
Drug Type
Small Molecule
Chemical Formula
C23H27FN4O2
CAS Number
106266-06-2
Unique Ingredient Identifier
L6UH7ZF8HC
Background

Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. Paliperidone, another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone).

Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively. Risperidone is thought to reduce this overactivity through inhibition of dopaminergic D2 receptors and serotonergic 5-HT2A receptors in the brain.

Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's binding affinity to D2 receptors, and carries lesser activity at several off-targets which may responsible for some of its undesirable effects.

Indication

Risperidone is indicated for the treatment of schizophrenia and irritability associated with autistic disorder. It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.

Risperidone is additionally indicated in Canada for the short-term symptomatic management of aggression or psychotic symptoms in patients with severe dementia of the Alzheimer type unresponsive to nonpharmacological approaches.

Risperidone is also used off-label for a number of conditions including as an adjunct to antidepressants in treatment-resistant depression.

Associated Conditions
Acute Mania, Irritability, Mixed manic depressive episode, Psychosis, Schizophrenia, Acute Manic episode, Agitated psychotic state
Associated Therapies
-

Risperidone Maintenance Treatment in Schizophrenia

Phase 4
Completed
Conditions
Interventions
First Posted Date
2009-02-20
Last Posted Date
2009-02-24
Lead Sponsor
Capital Medical University
Target Recruit Count
404
Registration Number
NCT00848432
Locations
🇨🇳

Beijing Anding Hospital of Capital Medical University, Beijing, China

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

First Posted Date
2009-02-16
Last Posted Date
2022-11-08
Lead Sponsor
Denovo Biopharma LLC
Target Recruit Count
261
Registration Number
NCT00845026
Locations
🇷🇺

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Samara, Russian Federation

Risperidone 1 mg Tablet in Healthy Subjects Under Fasting Conditions

Phase 1
Completed
Conditions
Interventions
First Posted Date
2009-01-27
Last Posted Date
2024-08-19
Lead Sponsor
Teva Pharmaceuticals USA
Target Recruit Count
30
Registration Number
NCT00830349
Locations
🇨🇦

Anapharm Inc., Sainte-Foy, Quebec, Canada

Risperidone 1 mg Tablets Dosed in Healthy Subjects Under Fed Conditions

Phase 1
Completed
Conditions
Interventions
First Posted Date
2009-01-27
Last Posted Date
2024-08-19
Lead Sponsor
Teva Pharmaceuticals USA
Target Recruit Count
24
Registration Number
NCT00829894
Locations
🇨🇦

Anapharm Inc., Sainte-Foy, Quebec, Canada

Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia

Phase 4
Completed
Conditions
Interventions
First Posted Date
2009-01-23
Last Posted Date
2011-12-23
Lead Sponsor
Chonnam National University Hospital
Target Recruit Count
58
Registration Number
NCT00827840
Locations
🇰🇷

Dept. of Psychiatry, Chonnam National Univeristy Hospital, Gwangju, Korea, Republic of

Pharmacological Treatment of Children and Adolescents With Severe Mood Dysregulation

Not Applicable
Conditions
First Posted Date
2009-01-21
Last Posted Date
2009-01-21
Lead Sponsor
Federal University of Rio Grande do Sul
Target Recruit Count
20
Registration Number
NCT00825552
Locations
🇧🇷

Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil

Dopamine D2 and D3 Receptor Occupancy and Clinical Response in Older Patients With Schizophrenia

First Posted Date
2009-01-19
Last Posted Date
2020-02-07
Lead Sponsor
Centre for Addiction and Mental Health
Target Recruit Count
14
Registration Number
NCT00825045
Locations
🇨🇦

Centre for Addiction and Mental Health, Toronto, Ontario, Canada

A Study to Evaluate the Efficacy and Safety of Seroquel in Chinese Han Patients With Schizophrenia

Phase 4
Completed
Conditions
Interventions
First Posted Date
2009-01-06
Last Posted Date
2010-06-15
Lead Sponsor
Shanghai Mental Health Center
Target Recruit Count
120
Registration Number
NCT00817648
Locations
🇨🇳

Mental Health Center of Luwan District, Shanghai, Shanghai, China

🇨🇳

Shanghai Mental Health Center, Shanghai, Shanghai, China

🇨🇳

Branch Hospital of Shanghai Mental Health Center, Shanghai, Shanghai, China

and more 1 locations

Treatment of Severe Childhood Aggression (The TOSCA Study)

First Posted Date
2008-11-24
Last Posted Date
2017-07-26
Lead Sponsor
Michael Aman
Target Recruit Count
168
Registration Number
NCT00796302
Locations
🇺🇸

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

🇺🇸

Ohio State University Nisonger Center, Columbus, Ohio, United States

🇺🇸

Case Western Reserve University, Cleveland, Ohio, United States

and more 1 locations

Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)

First Posted Date
2008-11-20
Last Posted Date
2012-07-16
Lead Sponsor
Joseph Blader
Target Recruit Count
270
Registration Number
NCT00794625
Locations
🇺🇸

Stony Brook University Medical Center, Stony Brook, New York, United States

🇺🇸

University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

🇺🇸

North Shore - LIJ Health System, Zucker Hillside Hospital, Glen Oaks, New York, United States

© Copyright 2024. All Rights Reserved by MedPath